15-Deoxi-Δ12,14-prostaglandin J2 is a tubulin-binding agent that destabilizes microtubules and induces mitotic arrest

Biochemical Pharmacology

Volumn 78, Issue 10, 2009, Pages 1330-1339

  Cocca, Claudia ^a   Dorado, Jorge ^a   Calvo, Enrique ^b   López, Juan Antonio ^b   Santos, Angel ^c   Perez Castillo, Ana ^a  

^a CSIC   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

15d PGJ2; Cancer; Cell death; Cytoskeleton; Mitosis; Tubulin

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ALPHA TUBULIN; BETA TUBULIN; CYSTEINE;

ANAPHASE; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL STRAIN MCF 7; CONTROLLED STUDY; COVALENT BOND; CYTOKINESIS; CYTOSKELETON; DEPOLYMERIZATION; DNA ADDUCT; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; METAPHASE; MICROTUBULE ASSEMBLY; MITOSIS; MITOSIS INHIBITION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION;

BINDING SITES; BIOTINYLATION; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; FEMALE; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MICROTUBULES; MITOSIS; MODELS, MOLECULAR; PPAR GAMMA; PROSTAGLANDIN D2; TUBULIN; TUBULIN MODULATORS;

EID: 70349440955     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.06.100     Document Type: Article

References (48)

1. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., and Willoughby D.A. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5 (1999) 698-701
2. Negishi M., and Katoh H. Cyclopentenone prostaglandin receptors. Prostaglandins Other Lipid Mediat 68-69 (2002) 611-617
3. Straus D.S., and Glass C.K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21 (2001) 185-210
4. Butler R., Mitchell S.H., Tindall D.J., and Young C.Y. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ 11 (2000) 49-61
5. Clay C.E., Namen A.M., Atsumi G., Willingham M.C., High K.P., Kute T.E., et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 20 (1999) 1905-1911
6. Nencioni A., Lauber K., Grunebach F., Van Parijs L., Denzlinger C., Wesselborg S., et al. Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling. J Immunol 171 (2003) 5148-5156
7. Pignatelli M., Cortes-Canteli M., Lai C., Santos A., and Perez-Castillo A. The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells. J Cell Sci 114 (2001) 4117-4126
8. Pignatelli M., Sanchez-Rodriguez J., Santos A., and Perez-Castillo A. 15-Deoxy-{Delta}-12,14-prostaglandin J2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism. Carcinogenesis 26 (2005) 81-92
9. Shimada T., Kojima K., Yoshiura K., Hiraishi H., and Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 50 (2002) 658-664
10. Tsubouchi Y., Sano H., Kawahito Y., Mukai S., Yamada R., Kohno M., et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 270 (2000) 400-405
11. Zander T., Kraus J.A., Grommes C., Schlegel U., Feinstein D., Klockgether T., et al. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem 81 (2002) 1052-1060
12. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 (1995) 813-819
13. Boyault S., Simonin M.A., Bianchi A., Compe E., Liagre B., Mainard D., et al. 15-Deoxy-delta12,14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. FEBS Lett 501 (2001) 24-30
14. Ward C., Dransfield I., Murray J., Farrow S.N., Haslett C., Rossi A.G., et al. D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism. J Immunol 168 (2002) 6232-6243
15. Gilroy D.W., Lawrence T., Perretti M., and Rossi A.G. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 3 (2004) 401-416
16. Castrillo A., Diaz-Guerra M.J., Hortelano S., Martin-Sanz P., and Bosca L. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages. Mol Cell Biol 20 (2000) 1692-1698
17. Clay C.E., Monjazeb A., Thorburn J., Chilton F.H., and High K.P. 15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. J Lipid Res 43 (2002) 1818-1828
18. Li L., Tao J., Davaille J., Feral C., Mallat A., Rieusset J., et al. 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J Biol Chem 276 (2001) 38152-38158
19. Nencioni A., Lauber K., Grunebach F., Brugger W., Denzlinger C., Wesselborg S., et al. Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-gamma-independent mechanism: regulation by inflammatory and T cell-derived stimuli. Exp Hematol 30 (2002) 1020-1028
20. Martinez B., Perez-Castillo A., and Santos A. The mitochondrial respiratory complex I is a target for 15-deoxy-D-12,14-prostaglandin J2 (15d-PGJ2) action. J Lipid Res 46 (2005) 736-743
21. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat Rev 4 (2004) 253-265
22. Pellegrini F., and Budman D.R. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 23 (2005) 264-273
23. Downing K.H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 16 (2000) 89-111
24. Wilson L., Panda D., and Jordan M.A. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct Funct 24 (1999) 329-335
25. Minotti A.M., Barlow S.B., and Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266 (1991) 3987-3994
26. Bu W., and Su L.K. Regulation of microtubule assembly by human EB1 family proteins. Oncogene 20 (2001) 3185-3192
27. Schneeweiss A., Sinn H.P., Ehemann V., Khbeis T., Neben K., Krause U., et al. Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. Int J Cancer 107 (2003) 346-352
28. Buey R.M., Calvo E., Barasoain I., Pineda O., Edler M.C., Matesanz R., et al. Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites. Nat Chem Biol 3 (2007) 117-125
29. Pignatelli M., Cocca C., Santos A., and Perez-Castillo A. Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene 22 (2003) 5446-5450
30. Chaffer C.L., Thomas D.M., Thompson E.W., and Williams E.D. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 6 (2006) 53
31. Kim E.H., Na H.K., Kim D.H., Park S.A., Kim H.N., Song N.Y., et al. 15-Deoxy-Delta12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS. Carcinogenesis 29 (2008) 688-695
32. Badano J.L., Teslovich T.M., and Katsanis N. The centrosome in human genetic disease. Nat Rev 6 (2005) 194-205
33. Sankaran S., and Parvin J.D. Centrosome function in normal and tumor cells. J Cell Biochem 99 (2006) 1240-1250
34. Srsen V., and Merdes A. The centrosome and cell proliferation. Cell Div 1 (2006) 26
35. Pihan G.A., Purohit A., Wallace J., Knecht H., Woda B., Quesenberry P., et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res 58 (1998) 3974-3985
36. Pihan G.A., Purohit A., Wallace J., Malhotra R., Liotta L., and Doxsey S.J. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 61 (2001) 2212-2219
37. Schneider Y., Chabert P., Stutzmann J., Coelho D., Fougerousse A., Gosse F., et al. Resveratrol analog (Z)-3,5,4′-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int J Cancer 107 (2003) 189-196
38. Jordan M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem 2 (2002) 1-17
39. Wilson L., and Jordan M.A. Microtubule dynamics: taking aim at a moving target. Chem Biol 2 (1995) 569-573
40. Lin H.L., Chang Y.F., Liu T.Y., Wu C.W., and Chi C.W. Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. Anticancer Res 18 (1998) 3443-3449
41. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., and Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56 (1996) 816-825
42. Woods C.M., Zhu J., McQueney P.A., Bollag D., and Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1 (1995) 506-526
43. Huang Y., Johnson K.R., Norris J.S., and Fan W. Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60 (2000) 4426-4432
44. Miller III M.C., Johnson K.R., Willingham M.C., and Fan W. Apoptotic cell death induced by baccatin III, a precursor of paclitaxel, may occur without G(2)/M arrest. Cancer Chemother Pharmacol 44 (1999) 444-452
45. Nabha S.M., Mohammad R.M., Dandashi M.H., Coupaye-Gerard B., Aboukameel A., Pettit G.R., et al. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 8 (2002) 2735-2741
46. Kanthou C., Greco O., Stratford A., Cook I., Knight R., Benzakour O., et al. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am J Pathol 165 (2004) 1401-1411
47. Kim E.H., and Surh Y.J. 15-deoxy-Delta12,14-prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factors. Biochem Pharmacol 72 (2006) 1516-1528
48. Britto P.J., Knipling L., and Wolff J. The local electrostatic environment determines cysteine reactivity of tubulin. J Biol Chem 277 (2002) 29018-29027